COVAX Facility and COVAX Advance Market Commitment Evaluability, Evaluation Design and Baseline Study

• Country: Switzerland
• Summary: COVAX Facility and COVAX Advance Market Commitment Evaluability, Evaluation Design and Baseline Study
• CHT Ref No: 52786684
• Deadline: 23 May 2021
• Financier: World Bank (WB)
• Purchaser Ownership: Government
• Tender Value: Refer Document
• Notice Type: Tender
• Document Ref. No.: 042-2021-GAVI-RFP
• Purchaser's Detail:
  Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.

  Login to see details
• Description:
• Request for proposals are invited for COVAX Facility and COVAX Advance Market Commitment Evaluability, Evaluation Design and Baseline study. Request for proposal (RFP) “COVAX Facility and COVAX Advance Market Commitment Evaluability, Evaluation Design and Baseline study” 042-2021-GAVI-RFP ISSUE DATE: 23 APRIL 2021 CLOSING DATE AND TIME: 23 MAY 2021 24:00 (CEST) Part 1: Introduction Gavi Alliance (“Gavi”), invites qualified bidders (herein after called “Bidder” or “Bidders”) to submit offers, consisting of a technical and a financial offer, together with any supporting documents (herein after called the “Proposal” or “Proposals”) for the provision of the requirements defined in this RFP document. In order to prepare a responsive Proposal, Bidders must carefully review and understand the contents of this covering letter, parts 1-6 of this RFP and the following key dates: Procurement Activity Responsible Party Due Date RFP Issue Date Gavi 23/04/2021 Error! Reference source not found. Intent to Participate due Bidder 02/05/2021 Final date for submitting Questions Bidder 02/05/2021 Gavi Response to Questions Gavi 06/05/2021 Bid submission deadline Bidder 23/05/2021/ 24:00 CEST Shortlisted Meetings Gavi/Bidder 31/05/2021 Estimated Contract Award Date Gavi 01/06/2021 Estimated Contract Start Date Gavi 16/06/2021 The proposed timeline set out above indicates the process Gavi intends to follow. If there are any changes to this time plan, Gavi will notify all Bidders of this in writing. Part 2: Gavi-s Requirements 2.0 Background Gavi Mission To save children-s lives and protect people-s health by increasing access to immunisation in poor countries. Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world-s children against some of the world-s deadliest diseases. The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill & Melinda Gates Foundation, and other private sector partners. Since its inception in 2000, Gavi has helped immunise a whole generation - over 822 million children - and prevented more than 14 million deaths, helping to halve child mortality in 73 developing countries. Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningitis, and yellow fever vaccines. After two decades of progress, Gavi is now focused on protecting the next generation and reaching the unvaccinated children still being left behind, employing innovative finance and the latest technology - from drones to biometrics - to save millions more lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency. Learn more at www.gavi.org. Gavi Project The Gavi Secretariat, partners and broader stakeholders are keen to ensure the successes, challenges and lessons learned from the COVAX Facility and COVAX Advance Market Commitment (AMC) are independently evaluated and documented, both from a learning and an accountability perspective. To this end, this study combines two important components that are intended to inform a future, more comprehensive evaluation plan:  First, an evaluability and evaluation design component that should ultimately help ensure robust evaluation work to follow.  Secondly, a baseline study that is intended to both inform potential course correction through early assessment of core design elements and to enable appropriate measurement over time of the effectiveness and performance of the COVAX Facility and COVAX AMC. 2.1 Scope of Work Broader context: the ACT-A Vaccine Pillar The Access to COVID-19 Tools - Accelerator (ACT-A), launched at the end of April 2020, brings together public and private expertise and institutions from around the world with a vision to create a global solution to expedite the end of the COVID-19 pandemic. It aims to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. The ACT-A is comprised of four technical partnerships: three vertical pillars (vaccines, therapeutics, and diagnostics) and one transversal health systems connector. The ACT-A partnerships include a broad and inclusive collaboration between diverse stakeholders, jointly leveraging their comparative advantages and respective constituencies to drive towards collective solutions to address COVID-19. This part of the RFP sets out the rules and requirements for participation. 042-2021-GAVI-RFP 5/25 The Vaccine Pillar is led by CEPI, Gavi and WHO and aims to speed up the search for effective vaccines and ensuring the equitable access to these across all countries. More information on the ACT-A and the Vaccine Pillar can be found: https://cepi.net/COVAX/ https://www.gavi.org/covax-facility https://www.who.int/initiatives/act-accelerator The COVAX Facility and the COVAX Advance Market Commitment (AMC) The COVAX Facility and the COVAX AMC are instruments contributing to the delivery of the ACT-A Vaccines Pillar. The goals of COVAX are:  To end the acute phase of the pandemic by end 2021  To deliver 2 billion doses of COVID-19 vaccine by end 2021  To guarantee fair and equitable access to COVID19 vaccines for all participating countries  To support the largest actively managed portfolio of COVID-19 vaccine candidates globally  To offer a compelling return on investment by delivering COVID19 vaccines as quickly as possible In July 2020, the Gavi Board approved Gavi as the legal entity to administer the COVAX Facility, a global mechanism to pool resources and demand for COVID-19 vaccines with the goal of accelerating the availability of This part of the RFP sets out the rules and requirements for participation. 042-2021-GAVI-RFP 6/25 and equitable access to safe and efficacious vaccines. The Board also approved the establishment of the Gavi COVAX AMC, a financing mechanism to accelerate and reserve COVID-19 vaccines to ensure that lowincome and lower middle-income economies (LICs and LMICs respectively), as well as other International Development Association (IDA) eligible economies, have access to COVID-19 vaccines at the same time as wealthier economies. The Facility, through securing legally binding agreements from self-financing participants (economies) will reserve doses with manufacturers and build an actively managed portfolio of 10-15 vaccine candidates based upon diverse technologies and geographies to maximise the chance of a successful outcome and accelerate access with up to two billion doses by end of 2021. The COVAX Facility will shape the vaccine market to expand supply and achieve economies of scale through aggregating demand and increasing availability simultaneously in developed and developing countries. The COVAX Facility is designed to ensure the procurement and governance needs of both Self-Financing Participants and 92 COVAX AMC-eligible economies are adequately addressed whilst minimising risks to Gavi core resources and programmes. The primary focus of the Gavi COVAX AMC is to ensure that the 92 LICs and LMICs that cannot fully afford to pay for COVID-19 vaccines themselves get equal access to COVID-19 vaccines as higher-income self-financing countries and at the same time. Funding for the Gavi COVAX AMC is entirely separate from that of the COVAX Facility, which means that the AMC is in no way cross-subsidised by the funds of self-financing participants. Instead, the AMC will be funded mainly through Official Development Assistance (ODA), as well as contributions from the private sector and philanthropy. More information on the COVAX Facility and COVAX AMC can be found here: https://www.gavi.org/vaccineswork/covax-explained 2.2 Objectives and scope of this assessment The scope of this RFP is focused on evaluability, a proposal for the design of COVAX Facility and COVAX AMC multi-stage evaluation (Evaluation), and a baseline study. The primary purpose of this evaluability, evaluation design and baseline study is to provide a foundation to help inform, steer and shape future evaluation related work to follow thereafter and to ensure a robust baseline is put in place. The primary purpose of this evaluability, evaluation design and baseline study is to provide a foundation to help inform, steer and shape future Evaluation related work to follow thereafter and to ensure a robust baseline is put in place. The baseline study, more specifically, is intended to both inform potential course correction through early assessment of core design elements and to enable appropriate measurement over time of the effectiveness and performance of the COVAX Facility and COVAX AMC. The primary audience for this evaluability, evaluation design and baseline study is the Gavi Board, and all partners and countries who are contributing to the COVAX efforts. It is important to note that the work to be commissioned in this RFP will be implemented in two phases: phase 1: evaluability and evaluation design; and phase 2: baseline study. While the expectation and intention are that the same bidder will complete both phases, the phase 2 baseline study component will only be given the green light based on satisfactory completion of phase 1: evaluability and evaluation design. The main objectives and scope of the study are as follows: This part of the RFP sets out the rules and requirements for participation. 042-2021-GAVI-RFP 7/25 Phase 1: Evaluability and Evaluation Design Component Evaluability Component Provide an independent assessment of the state of readiness / evaluability for the COVAX Facility and COVAX AMC multi-stage evaluation and provide suggestions to strengthen good quality future evaluation. To do this, the followin
• Documents:

 Tender Notice